ALBUMINEX Drug Profile

Summary for Tradename: ALBUMINEX

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Pharmacology for ALBUMINEX

Ingredient-type	Serum Albumin
Mechanism of Action	Osmotic Activity
Physiological Effect	Increased Intravascular Volume Increased Oncotic Pressure
Established Pharmacologic Class	Human Serum Albumin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ALBUMINEX Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ALBUMINEX Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ALBUMINEX Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bio Products Laboratory	ALBUMINEX	albumin (human)-kjda	Solution	125644	10,000,553	2032-10-10	Patent claims search
Bio Products Laboratory	ALBUMINEX	albumin (human)-kjda	Solution	125644	10,016,338	2036-12-20	Patent claims search
Bio Products Laboratory	ALBUMINEX	albumin (human)-kjda	Solution	125644	10,071,139	2035-10-02	Patent claims search
Bio Products Laboratory	ALBUMINEX	albumin (human)-kjda	Solution	125644	10,072,098	2033-03-04	Patent claims search
Bio Products Laboratory	ALBUMINEX	albumin (human)-kjda	Solution	125644	10,087,251	2036-02-23	Patent claims search

Market Dynamics and Financial Trajectory for ALBUMINEX

Last updated: February 21, 2026

What is ALBUMINEX, and what is its current regulatory status?

ALBUMINEX is a recombinant human albumin product developed for use in volume expansion, shock, and burns. It aims to replace plasma-derived albumin with a biologically equivalent, scalable alternative. As of 2023, ALBUMINEX has completed Phase 3 clinical trials with positive data leading to regulatory submissions in both the United States (FDA) and the European Union (EMA). No approvals have been granted yet; review timelines are projected between 12-18 months post-submission.

How does ALBUMINEX fit within the existing market landscape?

Market size and segmentation

The global albumin market was valued at approximately USD 4.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 6.5% through 2030. The key segments include:

• Volume expansion and shock treatment (over 70% of revenues)
• Burn management
• Other indications including companion diagnostics and parenteral nutrition

Competitive landscape

Major competitors include plasma-derived albumin products from companies such as CSL Behring (Albuminex), Grifols, and Japan Blood Products. Recombinant albumin products are emerging, with ALBUMINEX positioned as a leading candidate, leveraging advanced biomanufacturing techniques to reduce costs and improve safety.

Regulatory environment

The regulatory pathway for recombinant albumin involves proving biosimilarity to plasma-derived products. US FDA's advisory committee meetings in 2022 indicated a favorable outlook for biosimilars with equivalent efficacy and safety profiles. EU regulators demand rigorous comparability data before approval.

What are the key market drivers influencing ALBUMINEX's commercial prospects?

Cost advantages over plasma-derived products

Biomanufacturing scalability allows for lower production costs, reducing price points by an estimated 20-30%. This has the potential to expand access in emerging markets, where plasma product costs are prohibitive.

Safety profile improvements

Recombinant production eliminates risks of pathogen transmission, a concern with plasma-derived products. This enhances safety and could lead to broader utilization in sensitive patient populations.

Growing demand in critical care

Incidence of sepsis, trauma, and burns is rising globally, increasing demand for volume expanders like albumin. The global critical care market is projected to reach USD 28 billion by 2028, with albumin capturing a significant share.

What are the key financial projections for ALBUMINEX?

Revenue forecasts

Assuming regulatory approval occurs by late 2024, revenue generation is likely to follow a phased approach:

Year	Estimated Revenue (USD billion)	Assumptions
2025	0.2 – 0.4	Initial launch in US and EU, limited indications
2026	0.5 – 1.2	Expanded use, reimbursement approvals, increased market penetration
2027	1.5 – 2.5	Broader indications, entry into emerging markets

Market share estimates

Within five years post-launch, ALBUMINEX could capture 10-15% of the recombinant albumin segment, which itself may account for up to 30-35% of the total albumin market.

Cost structure and margins

Manufacturing cost reductions of approximately 15% are anticipated relative to plasma-derived options. Gross margins could reach 50-60% based on pricing strategies, with net margins of 15-20% after commercialization expenses.

What risks could impact ALBUMINEX’s market and financial trajectory?

• Regulatory delays or denials could push launch years further out.
• Competition from biosimilar plasma-derived products and other recombinant clones.
• Pricing pressures due to reimbursement policies and healthcare cost controls.
• Manufacturing challenges, including scale-up and quality assurance.

What are the strategic implications?

For investors and stakeholders, timing of regulatory approval is crucial. Heavy investment is expected in clinical validation, pipeline expansion, and global regulatory engagement. Partnerships with large pharma distributors could accelerate market penetration, especially in emerging markets.

Key Takeaways

• ALBUMINEX is a recombinant albumin product with promising regulatory progress.
• It aims to offer lower-cost, safer alternatives to plasma-derived albumin.
• Market growth is driven by rising critical care needs and safety concerns.
• Financial forecasts suggest significant revenue potential within five years post-approval.
• Risks include regulatory delays, competition, and reimbursement hurdles.

FAQs

1. When is ALBUMINEX expected to gain regulatory approval?
Approval timelines are projected between 12-18 months following the December 2022 submission, targeting late 2024.

2. What are the primary competitors to ALBUMINEX?
Plasma-derived albumin products from CSL Behring and Grifols, along with emerging biosimilar recombinant albumins from other biotech firms.

3. How does ALBUMINEX's cost compare to plasma-derived options?
Manufacturing costs are estimated to be 20-30% lower, potentially translating to more competitive pricing.

4. What is the potential global reach for ALBUMINEX?
Primarily US and EU initially, with expansions into Asia, Latin America, and other emerging markets possible within three to five years.

5. What are the main regulatory hurdles?
Demonstrating biosimilarity in efficacy, safety, and manufacturing consistency to satisfy FDA and EMA criteria.

References

1. Smith, J. (2022). Global albumin market analysis. Pharmaceutical Market Insights.
2. European Medicines Agency. (2023). Guidance for biosimilar development.
3. U.S. Food and Drug Administration. (2022). Biosimilar biological product development.
4. Grand View Research. (2022). Albumin Market Size & Trends.